• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

在受乳腺癌影响的非 BRCA1/2 同胞三家中,已知的低风险和中风险等位基因聚集,而不是新的隐性高风险基因。

Clustering of known low and moderate risk alleles rather than a novel recessive high-risk gene in non-BRCA1/2 sib trios affected with breast cancer.

机构信息

Department of Human Genetics, Leiden University Medical Centre, Leiden, The Netherlands.

Sequence Analysis Support Core, Leiden University Medical Centre, Leiden, The Netherlands.

出版信息

Int J Cancer. 2020 Nov 15;147(10):2708-2716. doi: 10.1002/ijc.33039. Epub 2020 May 30.

DOI:10.1002/ijc.33039
PMID:32383162
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7540545/
Abstract

Breast cancer risk is approximately twice as high in first-degree relatives of female breast cancer cases than in women in the general population. Less than half of this risk can be attributed to the currently known genetic risk factors. Recessive risk alleles represent a relatively underexplored explanation for the remainder of familial risk. To address this, we selected 19 non-BRCA1/2 breast cancer families in which at least three siblings were affected, while no first-degree relatives of the previous or following generation had breast cancer. Germline DNA from one of the siblings was subjected to exome sequencing, while all affected siblings were genotyped using SNP arrays to assess haplotype sharing and to calculate a polygenic risk score (PRS) based on 160 low-risk variants. We found no convincing candidate recessive alleles among exome sequencing variants in genomic regions for which all three siblings shared two haplotypes. However, we found two families in which all affected siblings carried the CHEK2*1100delC. In addition, the average normalized PRS of the "recessive" family probands (0.81) was significantly higher than that in both general population cases (0.35, P = .026) and controls (P = .0004). These findings suggest that the familial aggregation is, at least in part, explained by a polygenic effect of common low-risk variants and rarer intermediate-risk variants, while we did not find evidence of a role for novel recessive risk alleles.

摘要

乳腺癌风险在女性乳腺癌病例的一级亲属中约为普通人群的两倍。不到一半的风险可以归因于目前已知的遗传风险因素。隐性风险等位基因代表了家族风险剩余部分相对未被充分探索的解释。为了解决这个问题,我们选择了 19 个非 BRCA1/2 乳腺癌家族,其中至少有三个兄弟姐妹受到影响,而前一代或后一代的一级亲属没有乳腺癌。一个兄弟姐妹的种系 DNA 进行了外显子组测序,而所有受影响的兄弟姐妹都使用 SNP 芯片进行了基因分型,以评估单倍型共享并基于 160 个低风险变体计算多基因风险评分 (PRS)。我们在所有三个兄弟姐妹共享两个单倍型的基因组区域的外显子组测序变体中没有发现令人信服的候选隐性等位基因。然而,我们发现了两个家族,所有受影响的兄弟姐妹都携带 CHEK2*1100delC。此外,“隐性”家族先证者的平均归一化 PRS(0.81)明显高于普通人群病例(0.35,P =.026)和对照组(P =.0004)。这些发现表明,家族聚集至少部分是由常见低风险变体和罕见中等风险变体的多基因效应引起的,而我们没有发现新的隐性风险等位基因作用的证据。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c17c/7540545/9b63a10ac9ae/IJC-147-2708-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c17c/7540545/695ea2e96909/IJC-147-2708-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c17c/7540545/9b63a10ac9ae/IJC-147-2708-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c17c/7540545/695ea2e96909/IJC-147-2708-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c17c/7540545/9b63a10ac9ae/IJC-147-2708-g002.jpg

相似文献

1
Clustering of known low and moderate risk alleles rather than a novel recessive high-risk gene in non-BRCA1/2 sib trios affected with breast cancer.在受乳腺癌影响的非 BRCA1/2 同胞三家中,已知的低风险和中风险等位基因聚集,而不是新的隐性高风险基因。
Int J Cancer. 2020 Nov 15;147(10):2708-2716. doi: 10.1002/ijc.33039. Epub 2020 May 30.
2
A search for modifying genetic factors in CHEK2:c.1100delC breast cancer patients.寻找 CHEK2:c.1100delC 乳腺癌患者中可改变的遗传因素。
Sci Rep. 2021 Jul 20;11(1):14763. doi: 10.1038/s41598-021-93926-x.
3
Screening for BRCA1, BRCA2, CHEK2, PALB2, BRIP1, RAD50, and CDH1 mutations in high-risk Finnish BRCA1/2-founder mutation-negative breast and/or ovarian cancer individuals.在高危芬兰 BRCA1/2 种系突变阴性的乳腺癌和/或卵巢癌个体中筛查 BRCA1、BRCA2、CHEK2、PALB2、BRIP1、RAD50 和 CDH1 突变。
Breast Cancer Res. 2011 Feb 28;13(1):R20. doi: 10.1186/bcr2832.
4
Frequency of pathogenic germline variants in BRCA1, BRCA2, PALB2, CHEK2 and TP53 in ductal carcinoma in situ diagnosed in women under the age of 50 years.50 岁以下女性导管原位癌中 BRCA1、BRCA2、PALB2、CHEK2 和 TP53 种系致病性变异的频率。
Breast Cancer Res. 2019 May 6;21(1):58. doi: 10.1186/s13058-019-1143-y.
5
Identification of candidate cancer predisposing variants by performing whole-exome sequencing on index patients from BRCA1 and BRCA2-negative breast cancer families.通过对 BRCA1 和 BRCA2 阴性乳腺癌家族的索引患者进行全外显子组测序,鉴定候选癌症易感变异。
BMC Cancer. 2019 Apr 4;19(1):313. doi: 10.1186/s12885-019-5494-7.
6
Genomic profiling of CHEK2*1100delC-mutated breast carcinomas.CHEK2*1100delC 突变型乳腺癌的基因组分析
BMC Cancer. 2015 Nov 9;15:877. doi: 10.1186/s12885-015-1880-y.
7
Frequency of mutations in BRCA genes and other candidate genes in high-risk probands or probands with breast or ovarian cancer in the Czech Republic.在捷克共和国,高危先证者或有乳腺癌或卵巢癌先证者的 BRCA 基因和其他候选基因的突变频率。
Mol Biol Rep. 2020 Apr;47(4):2763-2769. doi: 10.1007/s11033-020-05378-7. Epub 2020 Mar 16.
8
BRCA1, BRCA2 and PALB2 mutations and CHEK2 c.1100delC in different South African ethnic groups diagnosed with premenopausal and/or triple negative breast cancer.在不同南非种族群体中,患有绝经前和/或三阴性乳腺癌的个体的BRCA1、BRCA2和PALB2基因突变以及CHEK2基因c.1100delC突变
BMC Cancer. 2015 Nov 17;15:912. doi: 10.1186/s12885-015-1913-6.
9
Genetic Predisposition to Breast Cancer Due to Mutations Other Than BRCA1 and BRCA2 Founder Alleles Among Ashkenazi Jewish Women.非 BRCA1 和 BRCA2 种系突变导致的阿什肯纳兹犹太裔妇女乳腺癌遗传易感性。
JAMA Oncol. 2017 Dec 1;3(12):1647-1653. doi: 10.1001/jamaoncol.2017.1996.
10
Genetic variants and haplotype analyses of the ZBRK1/ZNF350 gene in high-risk non BRCA1/2 French Canadian breast and ovarian cancer families.高危非BRCA1/2法裔加拿大乳腺癌和卵巢癌家族中ZBRK1/ZNF350基因的遗传变异和单倍型分析
Int J Cancer. 2008 Jan 1;122(1):108-16. doi: 10.1002/ijc.23058.

引用本文的文献

1
Hereditary cancer syndromes.遗传性癌症综合征
World J Clin Oncol. 2023 Feb 24;14(2):40-68. doi: 10.5306/wjco.v14.i2.40.

本文引用的文献

1
Addition of a 161-SNP polygenic risk score to family history-based risk prediction: impact on clinical management in non- breast cancer families.添加基于 161-SNP 多基因风险评分的家族史风险预测:对非乳腺癌家族临床管理的影响。
J Med Genet. 2019 Sep;56(9):581-589. doi: 10.1136/jmedgenet-2019-106072. Epub 2019 Jun 11.
2
Identification of deleterious germline CHEK2 mutations and their association with breast and ovarian cancer.鉴定有害的种系 CHEK2 突变及其与乳腺癌和卵巢癌的关联。
Int J Cancer. 2019 Oct 1;145(7):1782-1797. doi: 10.1002/ijc.32385. Epub 2019 May 20.
3
Polygenic Risk Scores for Prediction of Breast Cancer and Breast Cancer Subtypes.
多基因风险评分在乳腺癌及乳腺癌亚型预测中的应用。
Am J Hum Genet. 2019 Jan 3;104(1):21-34. doi: 10.1016/j.ajhg.2018.11.002. Epub 2018 Dec 13.
4
Association analysis identifies 65 new breast cancer risk loci.关联分析确定了65个新的乳腺癌风险位点。
Nature. 2017 Nov 2;551(7678):92-94. doi: 10.1038/nature24284. Epub 2017 Oct 23.
5
Compromised BRCA1-PALB2 interaction is associated with breast cancer risk.BRCA1与PALB2相互作用受损与乳腺癌风险相关。
Oncogene. 2017 Jul 20;36(29):4161-4170. doi: 10.1038/onc.2017.46. Epub 2017 Mar 20.
6
Genetic modifiers of CHEK2*1100delC-associated breast cancer risk.CHEK2*1100delC相关乳腺癌风险的基因修饰因子。
Genet Med. 2017 May;19(5):599-603. doi: 10.1038/gim.2016.147. Epub 2016 Oct 6.
7
Analysis of protein-coding genetic variation in 60,706 humans.对60706名人类的蛋白质编码基因变异进行分析。
Nature. 2016 Aug 18;536(7616):285-91. doi: 10.1038/nature19057.
8
Polygenic risk score is associated with increased disease risk in 52 Finnish breast cancer families.在52个芬兰乳腺癌家族中,多基因风险评分与疾病风险增加相关。
Breast Cancer Res Treat. 2016 Aug;158(3):463-9. doi: 10.1007/s10549-016-3897-6. Epub 2016 Jul 20.
9
Panel Testing for Familial Breast Cancer: Calibrating the Tension Between Research and Clinical Care.面板测试家族性乳腺癌:研究与临床护理之间的紧张关系的校准。
J Clin Oncol. 2016 May 1;34(13):1455-9. doi: 10.1200/JCO.2015.63.7454. Epub 2016 Jan 19.
10
Pathogenic and likely pathogenic variant prevalence among the first 10,000 patients referred for next-generation cancer panel testing.在最初10000例接受新一代癌症基因检测的患者中,致病性和可能致病性变异的患病率。
Genet Med. 2016 Aug;18(8):823-32. doi: 10.1038/gim.2015.166. Epub 2015 Dec 17.